Therapeutics Enzymes Market Forecasts to 2028 – Global Analysis By Product Type (Chitinase, Asparginase and Other Product Types), By Application (Leukemia, Stomach Disorders and Other Applications), By End User (Drug manufacturers, Hospitals, Private clin

Therapeutics Enzymes Market Forecasts to 2028 – Global Analysis By Product Type (Chitinase, Asparginase and Other Product Types), By Application (Leukemia, Stomach Disorders and Other Applications), By End User (Drug manufacturers, Hospitals, Private clinics and Research laboratories) and Geography

According to Stratistics MRC, the Global Therapeutic Enzymes Market is accounted for $8467.9 million in 2022 and is expected to reach $18684.8 million by 2028 growing at a CAGR of 14.1% during the forecast period. Enzymes and biocatalysts are produced in the human body from amino acids obtained from the digestion of food proteins. Therapeutic enzymes are a subset of enzymes that are used for medical purposes, either conjugated or isolated. These enzymes have a wide range of applications, including thrombolytics, oncolytics, anticoagulants, and replacements for certain metabolic deficiencies. Rising patient pool for leukaemia, other cancers, cardiovascular diseases, skin ulcers, and other diseases, increasing sedentary lifestyle responsible for increasing stress and subsequently giving rise to diseases, and improving healthcare services.

According to the American Cancer Society, 1,685,210 new cancer cases are expected to be diagnosed in the United States alone in 2016, while the World Health Organization reports that 17.7 million people died from cardiovascular diseases globally in 2015. This data demonstrates the market potential for cancer and cardiovascular therapeutics. Because therapeutic enzymes are important in the treatment of both diseases, their use is expected to increase over the forecast period.

Market Dynamics:

Driver:

Increasing number of cases

One of the most important factors expected to drive the growth of the therapeutic enzymes market is the rising number of cancer and cardiovascular disease cases worldwide. Furthermore, changes in lifestyle are to account for an increase in stress, which in turn is to account for an increase in the number of cases of pain disorders, raising the demand for therapeutic enzymes. Other factors that can boost revenue from the therapeutic enzymes market include rising healthcare expenditures, which are driving the adoption of advanced enzymes such as immobilised enzymes for therapeutic purposes.

Restraint:

Expensive doses

The therapeutic enzymes are quite expensive and face significant barriers to adoption, especially in developing nations. Therapeutic enzyme therapies are expensive, and less expensive alternatives are available on the market, which may limit the market. Furthermore, a lack of adequate government funding for various end uses in developing countries restrict market growth.

Opportunity:

Development of new approaches

The development of new approaches to cancer treatment using enzymes is a key trend that is gaining traction in the enzyme market. Major universities and corporations are investing in research aimed at developing new enzyme therapies for cancer treatment. For example, in August 2020, scientists from McGill University and Osaka University in Japan used the CMCF beamline at the Canadian Light Source (CLS) at the University of Saskatchewan to decipher the behaviour of an enzyme involved in the spread of cancer cells. Furthermore, rising awareness and a growing number of market players venturing into orphan disease management are driving market growth.

Threat:

Disease which cannot be cured

Factors that may limit the growth of therapeutic enzymes during the forecast period include the fact that therapeutic enzyme therapy cannot cure all tissues. Furthermore, some organs and tissues are more easily treated than others, and measuring efficacy is difficult. They are expensive, limiting patients' access.

Covid-19 Impact

Due to a severe shortage of hospital beds and medical equipment during the pandemic, global healthcare systems faced numerous difficult challenges. As a result, health-care systems are being impacted, and providing effective medical care and treatment to all patients has become a global challenge. The COVID-19 pandemic has reduced public mobility and impacted the diagnostic industries. Several non-emergent diagnostic procedures and therapies have been halted to prevent the spread of the novel coronavirus. Unfortunately, due to the strict lockdown norms, scheduled ERTs during COVID-19 were disrupted. Furthermore, the rising prevalence of cancer, which necessitates the use of drug-metabolizing enzymes (DMEs) for chemotherapy, is expected to propel the enzyme market forward in the coming years.

The Gaucher disease segment is expected to be the largest during the forecast period

During the forecast period, the Gaucher disease segment will have the largest market share. The high prevalence of Gaucher disease is an inherited condition caused by a recessive gene mutation. According to the National Library of Medicine, the disease is estimated to affect one in every 50,000 to 100,000 people in the general population, depending on the region. According to Clinicaltrials.gov, over 60 studies for Gaucher's disease are currently underway, with pharmaceutical companies funding the majority of them. As a result, rising awareness among pharmaceutical companies and the general public is expected to drive market growth in the near future.

The Hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment held the largest market share and were expected to have the highest CAGR during the forecast period. This is due to increased support from healthcare professionals and experts, closer monitoring, increased safety, and the availability of trained professionals with extensive experience in performing critical infusions.

Region with largest share:

During the forecast period, North America is expected to register largest share due to the highly improved and advanced healthcare services, rising prevalence of leukaemia, and growing population awareness in the region. Furthermore, this is attributed to the region's increased availability of infusion centres, increased acceptance of newer therapies, and increased prevalence of enzyme deficiency.

Region with highest CAGR:

Asia Pacific is expected to grow at a rapid pace, with the highest CAGR due to an increasing patient pool of cancers and diseases requiring therapeutic enzyme therapy. Moreover, expanding government and non-government initiatives to improve healthcare infrastructure are fueling the region's healthcare infrastructure. Such factors are boosting market growth in the Asia Pacific region.

Key players in the market

Some of the key players profiled in the Therapeutic Enzymes Market include Sanofi, BioMarin, AbbVie, F. Hoffmann-La Roche Ltd,Thermo Fisher Scientific Inc., Alexion, DSM, Novozymes, Horizon Pharma, Allergan, Johnson and Johnson , Alexion Pharmaceuticals Inc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, Roche Holdings AG and Codexis Inc.

Key Developments:

In January 2020, Codexis and Nestlé Health Science entered into a strategic collaboration with an aim to discover new enzyme therapy for potential treatment for GI disorders.

In October 2018, Leadiant Biosciences, Inc. Received the USFDA approval for Revcovi, a enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

Product Types Covered:
• Chitinase
• Asparginase
• Lipase
• Protease
• Nattokinase
• Serratiopeptidase
• Collagenase
• Ligase
• Other Product Types

Applications Covered:
• Leukemia
• Stomach Disorders
• Antitumor
• Skin Ulcers
• Gaucher disease
• Fabry disease
• Other Applications

End Users Covered:
• Drug manufacturers
• Hospitals
• Private clinics
• Research laboratories

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements